

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, H. G. Box 1459, Alexandria, VA 22313-1450, on the below date: 9. Box 1459, Alexandria, VA 22313-1450,

Name: Magdalena O. Cilella, Ph.D. Date: March 18, 2005

Signature:

BRINKS HOFER GILSON &LIONE

In re	Appln. of:			ED STATES PA	IENIA	ID IKAL	JEWARK	OF	FICE	
Appl	n. No.:	10/630,180`					Examir	er:	Not yet	assigned
Filed						Art Un	it:	1645		
For:		METHOD FOR MULTIPLE CHEMOKINE RECEPTOR SCREENING FOR ANTAGONISTS USING RAM ASSAY								
Attor	ney Docke	t No:	1070	9/47						
Comn P. O.	Stop Amendm nissioner for F Box 1450 ndria, VA 22	Patents				т	RANSI	/IT	TAL	
Sir:										
Attached is/are:										
\boxtimes	Second Sup	plementa	l Inform	ation Disclosure St	atement (in	duplicate)				
\boxtimes		m 1449 with copy of cited reference C1.								
\boxtimes	Return Rece	eipt Postc	ard.							
	alculation:									
\boxtimes	No additional fee is required.									
	An extension fee in an amount of \$ for amonth extension of time under 37 C.F.R. § 1.136(a).									
			····			Sma	all Entity		Not a S	mall Entity
	Claims Re After Ame			Highest No. Previously Paid For	Present Extra	Rate	Add'l Fee	or	Rate	Add'i Fee
Total			Minus			x \$9=			x \$18=	
Indep.			Minus			x 43=			x \$86=	
First Presentation of Multiple Dep. Claim					+\$145=			+ \$290=		
						Total	\$		Total	\$
Fee p	ayment:									
	A check in the amount of \$ to cover the above-identified fee(s) is enclosed.									
	Please charge Deposit Account No. 23-1925 in the amount of \$. A copy of this Transmittal is enclosed for this purpose.									
П										

Account No. 23-1925.

 \boxtimes

Magdalena O. Cilella, Ph.D. Registration No. 56,619

Respectfully submitted,

The Director is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this paper (including any extension fee required to ensure that this paper is timely filed), or to credit any overpayment, to Deposit



CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 18, 2005

Date of Deposit

Magdalena O. Cilella, Ph.D.

Name of Applicant, Assignee or Registered Representative

Signature

March 18, 2005

Date of Signature

Our Case No.: 10709/47

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Wei et al.

Examiner:

Serial No.: 10/630,180

0,180 Group Art Unit No.: 1645

Filing Date: July 30, 2003

For:

METHOD FOR MULTIPLE CHEMOKINE RECEPTOR

SCREENING FOR ANTAGONISTS

USING RAM ASSAY

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Second Supplemental Information Disclosure Statement be entered and the document listed below and on the attached Form PTO-1449 be considered by

the Examiner and made of record. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

The reference now cited is the following:

Other Art:

Loetscher et al., "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*", J Biol Chem 2001, 276(5):2986-91.

In accordance with 37 C.F.R. § 1.97(g),(h), this Second Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Second Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this First Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

This application is a continuation-in-part application of U.S. Serial No. 10/154,399, filed May 22, 2002 and is relied upon for an earlier filing dated under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of documents not previously cited and submitted to the Patent and Trademark Office in the prior application Serial No. 10/154,399 are enclosed for the convenience of the Examiner.

Applicant(s) respectfully request that the listed document be made of record in the present case.

Respectfully submitted,

3/18/05

Magdalena O. Cilella, Ph.D. Registration No. 56,619
Agent for Applicant

BRINKS HOFER GILSON & LIONE P.O. Box 10395 Chicago, IL 60610 (312) 321-4200

LOBM-8 60-1449	SERIAL NO.	CASE NO.
THE PARTY OF THE P	10/630,180	10709/47
LIST OF PATENTS AND PUBLICATIONS FOR	FILING DATE	GROUP ART UNIT
APPLICANT'S INFORMATION DISCLOSURE]
STATEMENT	July 30, 2003	1645
(use several sheets if necessary)	APPLICANTS: Weillet al	

REFERENCE DE	ESIGNATION	U.S. PATENT DOCUMENTS					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS/ SUBCLASS	FILING DATE		

FOREIGN PATENT DOCUMENTS EXAMINER DOCUMENT CLASS/ TRANSLATION SUBCLASS YES NO OUTPUT INITIAL NUMBER DATE COUNTRY SUBCLASS YES NO

EXAMINER INITIAL	OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)						
	C1	Loetscher et al., "The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3*", J Biol Chem 2001, 276(5):2986-91.					

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.